A Phase 1 interventional study of IY001(Finasteride) and IY002(Tamsulosin) in Healthy Adult Male, sponsored by Il-Yang Pharm. Co., Ltd.. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this stud is to evaluate the drug-drug interaction between IY001 and IY002 in adult males.
The study is an Open-label, Phase I, drug-drug interaction study.
Il-Yang Pharm. Co., Ltd. is the lead sponsor of 34 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Agree to use highly effective * (excluding hormonal methods) and refrain from donating sperm from the first dose until at least 4 weeks after the last dose of the investigational drugs. This includes agreement that the subject or their partner will avoid pregnancy.
*Highly effective contraception methods include: intrauterine device (IUD), bilateral tubal ligation, vasectomy of partner, or sexual abstinence. Methods such as periodic abstinence (calendar method, basal body temperature, ovulation method), withdrawal, use of spermicides alone, lactational amenorrhea, or simultaneous use of male and female condoms are not considered effective contraception.
Exclusion Criteria:
Within 1 month prior to the first dose:
Any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IY001 -\> IY001 + IY002
Drug: IY001(Finasteride) · Drug: IY002(Tamsulosin)
IY002 -\> IY001 + IY002
Drug: IY001(Finasteride) · Drug: IY002(Tamsulosin)
Subjects will receive IY001 once daily for 3 days, followed by co-administration of IY001 and IY002 once daily for 5 days.
Subjects will receive IY002 once daily for 5 days, followed by co-administration of IY001 and IY002 once daily for 3 days.
Finasteride Area Under the Curve during the dosing interval at steady state (AUCτ,ss)
The total drug exposure of finasteride over the dosing interval at steady state.
Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 3)
Finasteride Maximum Plasma Concentration at steady state (Cmax,ss)
The peak plasma concentration of finasteride observed at steady state.
Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 3)
Tamsulosin Area Under the Curve during the dosing interval at steady state (AUCτ,ss)
The total drug exposure of tamsulosin over the dosing interval at steady state.
Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 5)
Tamsulosin Maximum Plasma Concentration at steady state (Cmax,ss)
The peak plasma concentration of tamsulosin observed at steady state.
Time frame: Measured at steady state after repeated dosing.(Day 8 compared to Day 5)
Finasteride Time to Maximum Plasma Concentration at steady state (Tmax,ss)
Time to reach the maximum plasma concentration of finasteride measured from plasma samples collected at pre-dose and multiple post-dose time points on Days 3 and 8.
Time frame: Days 3 and 8
Finasteride Elimination Half-Life at Steady State (t1/2,ss)
The elimination half-life of finasteride calculated using plasma concentrations from serial blood samples collected up to 24 hours post-dose on Days 3 and 8.
Time frame: Days 3 and 8
Finasteride Apparent Clearance at Steady State (CLss/F)
Apparent clearance of finasteride derived from plasma concentration-time data obtained from serial blood sampling on Days 3 and 8.
Time frame: Days 3 and 8
Finasteride Minimum Plasma Concentration at Steady State (Cmin,ss)
Minimum plasma concentration measured from pre-dose (0 hour) samples collected on Days 1, 2, 7, and 8.
Time frame: Days 1, 2, 7, and 8
Finasteride Average Plasma Concentration at Steady State (Cav,ss)
Average plasma concentration calculated over the dosing interval from serial samples collected on Days 3 and 8.
Time frame: Days 3 and 8
Finasteride Accumulation Ratio (R)
Ratio of plasma concentrations comparing steady state (Day 8) to earlier dosing period (Day 3).
Time frame: Days 3 and 8
Finasteride Peak-Trough Fluctuation (PTF)
Fluctuation between peak (Cmax) and trough (Cmin) plasma concentrations calculated from serial sampling on Days 3 and 8.
Time frame: Days 3 and 8
Tamsulosin Time to Maximum Plasma Concentration at Steady State (Tmax,ss)
Time to reach the maximum plasma concentration of tamsulosin measured from plasma samples collected at pre-dose and multiple post-dose time points on Days 5 and 8.
Time frame: Days 5 and 8
Tamsulosin Elimination Half-Life at Steady State (t1/2,ss)
Elimination half-life calculated from plasma concentrations obtained up to 24 hours post-dose on Days 5 and 8.
Time frame: Days 5 and 8
Tamsulosin Apparent Clearance at Steady State (CLss/F)
Apparent clearance derived from plasma concentration-time data on Days 5 and 8.
Time frame: Days 5 and 8
Tamsulosin Minimum Plasma Concentration at Steady State (Cmin,ss)
Minimum plasma concentration measured from pre-dose samples collected on Days 1, 4, 7, and 8.
Time frame: Days 1, 4, 7, and 8
Tamsulosin Average Plasma Concentration at Steady State (Cav,ss)
Average plasma concentration over dosing interval calculated from serial samples on Days 5 and 8.
Time frame: Days 5 and 8
Tamsulosin Accumulation Ratio (R)
Ratio of plasma concentrations comparing steady state (Day 8) to earlier dosing period (Day 5).
Time frame: Days 5 and 8
Tamsulosin Peak-Trough Fluctuation (PTF)
Fluctuation between peak (Cmax) and trough (Cmin) plasma concentrations from serial sampling on Days 5 and 8.
Time frame: Days 5 and 8
Ran from Oct 2025 to primary completion in Dec 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Finasteride · Tamsulosin